Temasek subsidiary acquires M’sian healthcare firm

Temasek-HoldingsKUALA LUMPUR: Malaysia-based Aurum Healthcare Sdn Bhd has come under majority Temasek Holdings ownership through Accuron Technologies, a technology and engineering holding company, according to the Singapore Straits Times (SST).

Accuron Medtech Group, a division in Accuron Technologies, is the new owner of Aurum. This is the sixth medical technology related deal for Accuron Medtech Group.

“Our operating businesses provide therapeutic, diagnostic and medical device solutions to customers internationally through our direct presence in the US, Europe, China, Japan and Singapore,” said Abel Ang, group chief executive officer of Accuron Medtech. “By adding a commercial and manufacturing presence in Malaysia through Aurum, we believe this deal will be beneficial for our group operating companies.”

Accuron Medtech Group will place Aurum under Advanced Materials Technologies (AMT), its Singapore-based contract manufacturing partner. Aurum’s 20,000 sq ft facility in the Setia Business Park in Johor Bharu will be an addition to AMT’s 120,000 sq ft in Tuas, Singapore and a similar facility in Dongguan City in China.

Aurum can provide sterilization services for medical devices and instruments, according to the SST report, as well as clean room manufacturing and assembly services. “AMT specialises in metal injection moulding and 3D metal printing for high precision and complex metal parts used in the medical device sector.”

“This includes metal components found in endoscopes and robotic surgery instruments.”

In short, AMT will be able to expand its OEM (original equipment manufacturing) expertise given Aurum’s capabilities. The new areas for AMT will include plastic medical consumables used in heart by-pass surgeries, for example, catherisation and angiography procedures.

The medtech division wants to tap the opportunities in the global medtech market which is projected to be worth an estimated USD537 billion in 2020. The Asia-Pacific region, according to Accuron Technologies, would be the second largest market for medtech at USD133 billion by 2020.